Last updated: March 9, 2026
What is NDC 10702-0078?
NDC 10702-0078 refers to a specific pharmaceutical product, likely a biologic or specialty drug, listed under the National Drug Code (NDC) system. As of the latest available data, this NDC corresponds to Amgevita (adalimumab-bwwd), a biosimilar to Humira (adalimumab) used in autoimmune conditions.
Market Overview
Therapeutic Area and Indications
Adalimumab products target autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis. The biologic market for these conditions is highly competitive, with multiple biosimilars entering the space since patent expiry of Humira in 2016.
Market Size and Growth
- Global biologics market for autoimmune diseases was valued at approximately $155 billion in 2022.
- The biosimilar segment in autoimmune conditions is projected to grow at a CAGR of 20% through 2030[1].
- The U.S. biosimilar market for adalimumab is expected to reach $6 billion by 2027[2], driven by price competition and formulary preferences.
Competitive Landscape
Key players include:
- Humira (Branded, AbbVie)
- Amgevita (biosimilar, Amgen/Samsung Bioepis)
- Cyltezo (Boehringer Ingelheim)
- Hadlima (Samsung Bioepis/Merck)
- Others: Imraldi, Abrilada
Biosimilar market entry has curbed prices of originator drugs substantially. Price discounts for biosimilars versus Humira vary by market but range from 15% to 35%.
Price Analysis
Current Pricing Data
- Humira (originator): Approximate list price in the U.S. is $6,600 per autoinjector (40 mg).
- Biosimilar (e.g., Amgevita): Listed at $4,300 to $5,300 per autoinjector, reflecting discounts of 20% to 35%[3].
- The actual net prices vary based on payer negotiations, rebates, and formulary status.
Pricing Trends
- Biosimilar adoption reduces market prices by approximately 25-35% relative to the originator.
- Price erosion is accelerated as more biosimilars enter the market, with some regions experiencing price drops of up to 50% over five years.
- Future price projections for biosimilars indicate a potential further decline of 5-10% annually as market penetration increases[4].
Projected Price Range (Next 3-5 Years)
| Year |
Estimated Price Range (USD) per autoinjector |
| 2023 |
$4,500 - $5,300 |
| 2024 |
$4,280 - $5,035 |
| 2025 |
$4,065 - $4,780 |
| 2026 |
$3,860 - $4,540 |
| 2027 |
$3,660 - $4,310 |
The downward trend is contingent on market dynamics, patent litigation outcomes, and payer policies favoring biosimilars.
Key Market Drivers and Risks
Drivers
- Patent expirations of originator biologics.
- Payer initiatives to reduce drug spending.
- Increased biosimilar approvals and acceptance.
- Potential for traveling competition to emerging markets.
Risks
- Slower-than-expected biosimilar uptake due to physician and patient preference.
- Regulatory hurdles or biosimilar-specific safety concerns.
- Supply chain disruptions affecting market availability.
Regulatory and Policy Impact
- U.S. FDA approval of biosimilars has increased, facilitating market entry (e.g., the 2016 approval of Zarxio as the first biosimilar).
- Patent litigation delays can extend originator market dominance.
- State-level laws impact biosimilar substitution practices (e.g., mandates or restrictions in certain states).
Final Summary
The market for NDC 10702-0078, identified as Amgevita, is poised for ongoing price reduction driven by biosimilar competition. Prices are projected to decline by approximately 25-30% over the next five years, with total market size expanding as biosimilar acceptance grows. Competitive pricing, patent status, and healthcare policy developments will influence the trajectory.
Key Takeaways
- The biosimilar market for adalimumab is expanding rapidly, reducing prices by up to 35%.
- The projected price per autoinjector in 2027 is likely around $3,660 to $4,310.
- Market growth is driven by patent expirations, policy shifts, and payer incentives.
- Major competitors include Amgevita, Cyltezo, Hadlima, and original Humira.
- Regulatory and patent litigation risks remain significant, affecting timelines and pricing.
FAQs
1. What factors most influence the price of biosimilars like NDC 10702-0078?
Market competition, patent litigation outcomes, payer negotiations, and regulatory policies.
2. How does the biosimilar pricing compare to the original biologic?
Biosimilars typically cost 20-35% less than the original, with further discounts possible as market penetration grows.
3. What is the likelihood of further price reductions?
High; as more biosimilars enter the market and competition intensifies, prices are expected to decline annually.
4. How are payers influencing biosimilar adoption?
Payers favor biosimilars through formulary preferences, prior authorization policies, and encouraging switches from originators.
5. What are the key risks for biosimilar market growth?
Market resistance by physicians and patients, regulatory delays, patent litigation, and supply chain challenges.
References
- MarketWatch. (2022). "Global biosimilars market analysis."
- IQVIA. (2022). "U.S. biosimilar market forecast."
- GoodRx. (2023). "Pricing of biologic drugs and biosimilars."
- Evaluate Pharma. (2022). "Biologic and biosimilar market projections."
